Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Psyched：5-meo-DMT 治疗抑郁症、提供治疗的犹他州医院、埃隆·马斯克和 Meta 的影响力
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
鼻内 5-meo-DMT 临床试验为耐药性抑郁症带来希望
Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a study of Beckley's novel formulation of 5-MeO-DMT in Treatment Resistant Depression (TRD.)
合作伙伴Beckley Psytech和atai Life Sciences（纳斯达克股票代码：ATAI）共同宣布了一项针对贝克利治疗耐药性抑郁症（TRD）的5-meo-DMT新配方的2a期研究的积极初步结果。
BPL-003 is a synthetic and patent-protected benzoate salt formulation of 5-MeO-DMT (aka mebufotenin) designed for intranasal administration. The open-label study assessed safety, tolerability and efficacy of the compound at a single 10mg dose, alongside psychological support, in patients with moderate-to-severe TRD (who withdrew from concomitant antidepressants.) Learn more.
BPL-003 是一种受专利保护的 5-meo-DMT（又名美布替宁）的合成苯甲酸盐配方，专为鼻内给药而设计。这项开放标签研究评估了该化合物在单剂量10mg下的安全性、耐受性和疗效，以及心理支持，适用于中度至重度TRD患者（已停用联合抗抑郁药）。了解更多。
Utah Hospitals Will Soon Provide...
犹他州医院...
登录免费看全文
登录/注册
资讯热榜
更新时间